A major breakthrough in understanding diabetes mellitus, especially in the disease cystic fibrosis (CF) was made recently by the group of Dr. Hsiao Chang Chan from the Epi- Dr. Chan and colleagues first showed that β cells express CFTR and CFTR is activated by glucose to increase Cl  current and control intracellular Cl  concentration in these cells. Most notably, the most common human mutation that causes CF, ΔF508, when introduced in mice, caused hyperpolarization of the β cell membrane potential. Moreover, manipulation of CFTR activity showed that CFTR Cl  current was required to prevent hyperpolarization of the membrane potential. Absence of CFTR activity was sufficient to reduce the depolarization caused by glucose-mediated inhibition of the ATP-regulated K + channels. Thus, in the absence of CFTR activity, the glucose-evoked β cell action potentials were reduced and consequently insulin secretion.
As expected from the findings with β cells, mice with mutated CFTR have lower insulin levels than wild-type mice, and show reduced response to glucose. Most excitedly, Dr. Chan and co-workers showed that treatment of the mice with drugs developed to treat CF also corrected insulin secretion. These drugs are already in the clinic or are being tested with patients, thus they are very promising therapy in CF patients and may be even used in other forms of diabetes to boost insulin secretion.
